陈兴栋

主要研究方向为大型队列建设、重大慢性疾病的分子流行病学和遗传学研究。

陈兴栋，复旦大学研究员/博导，复旦大学公共卫生学院副院长，复旦大学泰州健康科学研究院院长。泰州队列负责人，四大慢病重大专项项目首席，国家优青，上海东方学者、曙光学者。主要研究方向为大型队列建设、重大慢性疾病的分子流行病学和遗传学研究。近5年，以第一及通讯作者在Nature Microbiology、Cell Metabolism、Innovation、Gut等国际学术期刊发表研究论文100余篇，H-Index 60，主持15项国家省部级纵向项目和横向项目，累积经费约2.7亿元。授权发明专利4项，获软件著作权11项，出版专著3部，牵头立项5项国家标准，以第一完成人荣获江苏省科技进步奖二等奖、第二完成人荣获山东省科学技术进步奖二等奖。

中国医药生物技术协会生物样本库常务委员、全国生物样本标准化技术委员会（SAC/TC559）委员、中国研究型医院学会临床数据与样本资源库专业委员会信息学组委员、国家自然科学基金委医学科学部2023年度基金项目评审会评专家、“福声计划”中国人群泛癌早筛前瞻性研究学术专家委员会顾问和 Phenomics 期刊青年编委会成员。

江苏省科技进步奖二等奖、山东省科学技术进步奖二等奖、2024年第一季度“Wiley威立中国开放科学高贡献作者”等。

论文：

(1)Ning-Ning Liu#, Na Jiao#, Jing-Cong Tan#, Ziliang Wang#, Dingfeng Wu, An-Jun Wang, Jie Chen, Liwen Tao, Chenfen Zhou, Wenjie Fang, Io Hong Cheong, Weihua Pan, Wanqing Liao, Zisis Kozlakidis, Christopher Heeschen, Geromy G. Moore, Lixin Zhu*, Xingdong Chen*, Guoqing Zhang*, Ruixin Zhu*, Hui Wang*. Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nature Microbiology. 2022. 7(2): 238-250.

(2)Yunzi Mao, Mei Cui, Yanfeng Jiang, Haowen Yu, Meng Wang, Gang Li, Haihui Zhang, Cheng Zhao, Yanxin Shen, Yupeng Hu, Yanpeng An, Yan Lin, Yiyuan Yuan, Pengcheng Lin, Xingdong Chen*, Wei Xu*, Shi-Min Zhao*. AMPKα2 signals amino acid insufficiency to inhibit protein synthesis. Cell Metabolism. 2026. 38(1):192-207.e8.

(3)Huangbo Yuan#, Yanfeng Jiang#, Zhenqiu Liu#, Renjia Zhao, Ziyu Yuan, Qiuhong Man, Shaohui Liu, Hongxuan Zhang, Lijuan Xu, Yunzhi Zhang, Zhixi Su, Qiye He, Kelin Xu, Tiejun Zhang, Li Jin, Ming Lu, Weimin Ye, Jiangli Zhang, Rui Liu*, Chen Suo*, Xingdong Chen*. Leveraging biomarkers and primary care embedding for scalable precision cancer prevention in China: Insights from the FuSion study. Innovation. 2025. 7(3):101189.

(4)Zhenqiu Liu#, Chunqing Lin#, Xianhua Mao#, Chengnan Guo, Chen Suo, Dongliang Zhu, Wei Jiang, Yi Li, Jiahui Fan, Ci Song, Tiejun Zhang, Li Jin, Catherine de Martel, Gary M Clifford*, Xingdong Chen*. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 2023. 72(12): 2354-2363.

(5)Yanfeng Jiang#, Mei Cui#, Weizhong Tian, Sibo Zhu, Jinhua Chen, Chen Suo, Zhenqiu Liu, Ming Lu, Kelin Xu, Min Fan, Jiucun Wang, Qiang Dong, Weimin Ye, Li Jin, Xingdong Chen*. Lifestyle, multi-omics features, and preclinical dementia among Chinese: The Taizhou Imaging Study. Alzheimer's & Dementia. 2021. 17(1): 18-28.

(6)henqiu Liu#, Yanfeng Jiang#, Huangbo Yuan, Qiwen Fang, Ning Cai, Chen Suo, Li Jin, Tiejun Zhang*, Xingdong Chen*. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. Journal of Hepatology. 2019. 70(4): 674-683.

(7)Tao Jiang, Hongzhe Guo, Yadong Liu, Gaoyang Li, Zhe Cui, Xinran Cui, Yue Liu, Yang Li, Anqi Zhang, Shuqi Cao, Tianyi Zhao, Liran Juan, Weize Kong, Ming Chen, Dianming Liu, Hongri Liu, Yixiao Zhang, Kelin Xu, Yongjun Wang, Meian He, Jiancheng Guo, Ming Lu, Jun Chen, Xing Zhao, Genming Zhao, Shaonong Dang, Chao Chen, Xiaojian Wu, Qiyuan Qin, Yixue Li, Hongbing Shen, Li Jin, Bo Liu*, Xingdong Chen*, Yuhong Zhao*, Yadong Wang*. A comprehensive genetic variant reference for the Chinese population. Science bulletin. 2024. 69(24): 3820-3825.

(8)Mei Cui#, Yanfeng Jiang#, Qianhua Zhao, Zhen Zhu, Xiaoniu Liang, Kexun Zhang, Wanqing Wu, Qiang Dong, Yanpeng An, Huiru Tang, Ding Ding*, Xingdong Chen*. Metabolomics and incident dementia in older Chinese adults: the Shanghai Aging Study. Alzheimer’s & Dementia. 2020. 16(5): 779-788.

(9)Ying Yu#, Hao Xue#, Chen Suo#, Hui Wang, Yanyu Pang, Chunhui Ji, Wanwan Hou, Yuting Lu, Dantong Lu, Leqing Sang, Jia Xu, Chenbiao Li, Li Jin, Leming Shi, Jiayun Zhang*, Ji Liang*, Weiwei Zhao*, Xingdong Chen*. Palliative Care Educational App for Family Caregivers of Homebound Patients With Incurable Cancer : A Single-Center Randomized Trial. Annals of internal medicine. 2025. 178(12):1737-1751.

(10)Zhenqiu Liu, Xuehong Zhang, Xingdong Chen*. Body Mass Index and PNPLA3 Genetic Variant Modify the Association of Alcohol Consumption With Liver Fat Content. Clinical Gastroenterology and Hepatology. 2022. 20(11): 2659-2660.

专利：

（1）专利名称：动脉粥样硬化的识别模型的构建方法，专利号：ZL201810010227.2，授权日期：20230310

（2）专利名称：一种单细胞转录组的测序方法（授权），专利号：ZL201711447883.0，授权日期：20221111

（3）专利名称：一组人永生化B淋巴细胞系的建立和应用，专利号：ZL201711309755.X，授权日期：20230404

（4）专利名称：一种高灵敏的磁珠分选联合胶体金标记的外泌体免疫电镜方法，专利号：ZL201910032544.9，授权日期：20230822

（1）中华人民共和国国家卫生健康委员会，四大慢病重大专项，2023ZD0510000，中国自然人群示范队列（泰州队列）建设研究，2024-08至2028-07，主持

（2）中华人民共和国国家卫生健康委员会，国家重点研发计划课题，2024YFC3405801，跨尺度多维数据云平台及多模态数据库构建研究，2024-12至2027-11，主持

（3）国家自然科学基金委员会，优秀青年科学基金项目，82122060，肿瘤分子流行病学，2022-01至2024-12，主持

（4）中华人民共和国科学技术部，国家重点研发计划，2017YFC0907002，江苏省沿江地区自然人群队列研究，2017-07至2020-12，主持

（5）国家自然科学基金委员会，面上项目，82073637，体细胞突变特征解析食管鳞癌暴露因素致病机制研究，2021-01至2024-1，主持

无。

Xingdong Chen, Researcher and Doctoral Supervisor of Fudan University, Vice Dean of School of Public Health, Fudan University, Dean of Taizhou Institute of Health Sciences, Fudan University.

As the person in charge of Taizhou Cohort Study, Chief Scientist of Major Special Project on Four Major Chronic Diseases, recipient of National Outstanding Youth Fund, Shanghai Oriental Scholar and Shanghai Dawn Scholar.

Academic appointments include Standing Committee Member of Biobank Branch, Chinese Association of Medical Biotechnology, Member of National Technical Committee for Biobank Standardization (SAC/TC559), Member of Informatics Group, Committee of Clinical Data and Sample Resource Banks of Chinese Research Hospital Association, Member of National Professional Committee for Medical and Health Data Processing, and Advisor to Academic Expert Committee of FuSion Program Prospective Study on Population-based Pan-cancer Early Screening in China.

Core research focuses on large-scale cohort establishment, molecular epidemiology and genetic research of major chronic diseases. Over the past five years, more than 100 SCI papers have been published as first and corresponding authors on international journals including Nature Microbiology, Cell Metabolism, Innovation and Gut, the H-index reaches 60. A total of 15 national, provincial, ministerial vertical and horizontal research projects have been undertaken, with accumulated research funds reaching approximately 270 million RMB.

Possess 4 authorized invention patents, 11 software copyrights and 3 published monographs, and take the lead in formulating 5 national standards. Awarded the Second Prize of Jiangsu Provincial Science and Technology Progress Award as the first accomplisher, and the Second Prize of Shandong Provincial Science and Technology Progress Award as the second accomplisher.